Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease
Extension to a Multicenter, Open-label Study to Assess the Safety and Efficacy of 600 μg SOM230, Administered Subcutaneously, Bid in Patients With Cushing's Disease